Daratumumab After Transplant for High-Risk T-Cell Leukemia or Lymphoma in Young People
Tests daratumumab after transplant in young people with high-risk T-cell leukemia or lymphoma.
Key facts
- Who runs it
- New York Medical College
- Where
- Aurora, Boston, Columbus, Gainsville, Grand Rapids, Houston, Indianapolis, Loma Linda, Los Angeles, Milwaukee, Philadelphia, Phoeniz, San Francisco, St. Petersburg, Vallhala, and Washington D.C., United StatesSee the 16 sites
- Trial code
- Registry title
- Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 22 May 2023
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- Daratumumab
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teens and young adults with high risk T-cell leukemia or T-cell lymphoma who are about to have a stem cell transplant from a donor. It tests the safety of daratumumab given after the transplant.
- Age
- 0 to 39 years
- Sex
- All sexes can join.
- Disease stage
- T-cell ALL in second or later remission (5% blasts or less), or T-cell lymphoblastic lymphoma that relapsed and then had a complete response after re-induction treatment. A secondary cancer is included.
- Earlier treatment
- A donor stem cell transplant must be planned, with a donor already found. People must have fully recovered from the acute side effects of earlier chemotherapy, immunotherapy or radiotherapy. They cannot have had a stem cell transplant before.
Main reasons for not taking part
- Earlier autologous or allogeneic stem cell transplant
- Uncontrolled infection throughout the body
- Pregnant or actively breast feeding
- Positive for HIV, hepatitis B or hepatitis C
- Known allergy to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- 0-39yrs
- T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy (including secondary malignancy)
- Planned allogeneic stem cell transplantation with donor identified
- Performance status ≥ 60%
- Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
- Meet organ function requirements
- Signed IRB approved informed consent
Who cannot take part
- May not have had a prior autologous or allogenic stem cell transplant
- May not have uncontrolled, systemic infection at the time of enrollment
- Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients
- Seropositive for HIV, hepatitis B or hepatitis C
- Clinically significant cardiac disease
- Must not be pregnant or actively breast feeding
- COPD
- Asthma
Where in United States
- Children's Hospital ColordaoAurora, United StatesContact: Taymour Hammoudi, MDNot yet recruiting
- Boston Children's HospitalBoston, United StatesContact: Amy Keating, MDTaking people
- Nationwide Children's HosptialColumbus, United StatesContact: Lauren Harrison, RN, MSNNot yet recruiting
- University of FloridaGainsville, United StatesContact: Jordan Milner, MDTaking people
- Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Troy Quigg, DOTaking people
- MD Anderson Cancer CenterHouston, United StatesContact: Lauren Harrison, RN, MSNNot yet recruiting
- Riley Children's HospitalIndianapolis, United StatesContact: April Rahrig, MDTaking people
- Loma Linda University Children's HospitalLoma Linda, United StatesContact: Hisham Abdel-Azim, MDTaking people
- University of CaliforniaLos Angeles, United StatesContact: Ted Moore, MDNot yet recruiting
- Medical College of WisconsinMilwaukee, United StatesContact: Lauren Harrison, RN, MSNNot yet recruiting
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Alix Seif, MDTaking people
- Phoenix Children's HospitalPhoeniz, United StatesContact: Lauren Harrison, RN, MSNNot yet recruiting
- University of CaliforniaSan Francisco, United StatesContact: Rohini Jain, MDTaking people
- John Hopkins All Children's HospitalSt. Petersburg, United StatesContact: Lauren Harrison, RN, MSNNot yet recruiting
- New York Medical CollegeVallhala, United StatesContact: Mitchell Cairo, MDTaking people
- Children's National Medical CenterWashington D.C., United StatesContact: Anant Vatsayan, MBBSNot yet recruiting
About the trial
What the trial wants to find out
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).
Read full original descriptionShow less
Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
The group in the trial
- InterventionalOther group
Phase 1: 3 dose levels to determine safety (15 patients) Dose expansion: Daratumumab (DARA) treatment post-HCT 1. Induction: DARA IV weekly x 8 doses (Weeks 1-8) 2. Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24) 3. Maintenance: DARA IV every 4 weeks (Stop at Day +270)
Treatment: Daratumumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)
- Plain-language title
- Daratumumab After Transplant for High-Risk T-Cell Leukemia or Lymphoma in Young PeopleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 September 2026